http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107892672-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107892672-B |
| titleOfInvention | Branched 2-nitroimidazole compound and application thereof in hypoxia-selective antitumor prodrug |
| abstract | The invention discloses a branched 2-nitroimidazole compound and application thereof in hypoxia-selective antitumor prodrug, wherein the compound has a structure shown in a general formula I, wherein R 1 、R 2 Including but not limited to the following structures: hydrogen, methyl. The compound can target to a tumor hypoxia area and is reduced by high-expression specific enzyme in hypoxic tumor tissues, so that an active drug is released. The compound provided by the invention can be connected with ligands and antitumor drugs, is applied to a hypoxia-selective antitumor prodrug, improves the solubility of the drugs, improves the targeting property, reduces the toxic and side effects, and enhances the antitumor curative effect. |
| priorityDate | 2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.